In skeletal muscle, L-type calcium channels (DHPRs), localized to plasma membrane sarcoplasmic reticulum junctions, are tightly packed into groups of four termed tetrads. Here, we have used bimolecular fluorescence complementation (BiFC) and targeted biotinylation to probe the structure and organization of \( \beta_1a \) subunits associated with native CaV1.1 in DHPRs of myotubes. The construct YN-\( \beta_1a \)-YC, in which the non-fluorescent fragments of YFP ("YN" corresponding to YFP residues 1–158, and "YC" corresponding to YFP residues 159–238) were fused, respectively, to the N- and C-termini of \( \beta_1a \), was fully functional and displayed yellow fluorescence within DHPR tetrads after expression in \( \beta_1 \)-knockout (\( \beta_1 \)-KO) myotubes; this yellow fluorescence demonstrated the occurrence of BiFC of YN and YC on the \( \beta_1a \) N- and C-termini. In these experiments, we avoided overexpression because control experiments in non-muscle cells indicated that this could result in non-specific BiFC. BiFC of YN-\( \beta_1a \)-YC in DHPR tetrads appeared to be intramolecular between N- and C-termini of individual \( \beta_1a \) subunits rather than between adjacent DHPRs because BiFC (1) was observed for YN-\( \beta_1a \)-YN co-expressed with CaV1.2 (which does not form tetrads) and (2) was not observed after co-expression of YN-\( \beta_1a \)-YN plus YC-\( \beta_1a \)-YC in \( \beta_1 \)-KO myotubes. Thus, \( \beta_1a \) function is compatible with N- and C-termini being close enough together to allow BiFC. However, both termini appeared to have positional freedom and not to be closely opposed by other junctional proteins since both were accessible to gold-streptavidin conjugates. Based on these results, a model is proposed for the arrangement of \( \beta_1a \) subunits in DHPR tetrads.

Introduction

Two major proteins involved in skeletal muscle excitation-contraction (EC) coupling are the dihydropyridine receptor (DHPR) localized in the plasma membrane and the ryanodine receptor type 1 (RyR1) residing in the sarcoplasmic reticulum (SR) membrane. DHPRs in skeletal muscle are arrayed in groups of four, termed tetrads, positioned over the homotetrameric subunits of every other RyR1. The DHPR acts as an L-type Ca\(^{2+}\) channel and as the transducer that links electrical excitation to muscle contraction. Specifically, DHPR voltage sensing domains translocate in response to membrane depolarization causing the pore-forming regions of the channel to open and to flux Ca\(^{2+}\), although this Ca\(^{2+}\) current is not necessary for skeletal muscle EC coupling. Instead, it is thought that depolarization-induced conformational changes of the DHPR are somehow transmitted to RyR1, causing it to open and release Ca\(^{2+}\) from the SR, which in turn elicits muscle contraction.

The skeletal muscle DHPR is a hetero-pentamer comprised of CaV1.1, \( \beta_1a \), \( \gamma_1 \) and \( \delta_\) subunits. EC coupling is still functional following knockout of \( \gamma_1 \) or suppression of \( \delta_\) by siRNA. By contrast, mice null for either CaV1.1 or \( \beta_1 \) die at birth as of consequence of failed EC coupling and respiratory paralysis. CaV1.1 is a typical, four-repeat, voltage-gated ion channel and houses both the voltage sensing structures and the ion conducting pore. The loop between domains II-III has been
shown to be vital for skeletal muscle EC coupling, and the I-I cytoplasmic loop binds the channel auxiliary β subunit. CaVβ subunits are encoded by four distinct genes (β1, β2, β3 and β4) with multiple splice variants. Based on primary sequence, β subunits are comprised of five domains (D1-D5); two of these, D2 (or SH3) and D4 (or GK) are strongly conserved, and three (D1, D3 and D5) are highly divergent. Crystals of the β subunit core (D2-D4) reveal structural similarities to PSD-95, a membrane-associated guanylate kinase (MAGUK) protein. The β subunit D3 and D4 tetrads have sequence and structure similarity, respectively, to the Src homology 3 (SH3) and guanylate kinase (GK) domains of PSD-95. Because they are unstructured, the orientation of the D1, D3 and D5 domains, both in free β subunits and within assembled CaVα channels, remains unknown.

The β subunit core plays an important role in membrane trafficking of high-voltage activated CaV channels, including CaV1.1. However, studies of β subunit expression in myotubes obtained from mice with a knocked-out β1 gene (β1KO myotubes) indicate that β1 also has a more direct role in skeletal-type EC coupling. In particular, skeletal-type EC coupling, but not membrane trafficking of CaV1.1, is suppressed by truncation or alteration of the C-terminal (D5) domain of β1. Given the importance of the β1 C-terminal, and the lack of information about its orientation, as well as that of the N-terminal, the goal of the studies described here was to probe this orientation by means of bimolecular fluorescence complementation (BiFC) and targeted biotinylation.

BiFC23,24 employs two non-fluorescent fragments of yellow fluorescent protein (YFP), YFP-N (YN: residues 1–158) and YFP-C (YC: residues 159–238). When expressed together as individual fragments in living cells, complementation, and subsequent yellow fluorescence, is insufficient and dim. This complementation, or BiFC, is greatly enhanced when the two fragments are attached to proteins or protein domains that interact with each other. An advantage of this approach, compared with fluorescence resonance energy transfer (FRET), is that BiFC can provide information from a single excitation/emission image without the resonance energy transfer (FRET), is that BiFC can provide information from a single excitation/emission image without the

As one approach for probing the spatial relationships between the N- and C-termini of the β1a subunit of the skeletal muscle L-type CaV channel (DHPR), we tested whether BiFC would occur for YFP amino acids 1–158 ("YN") and 159–238 ("YC") fused to the β1a N- and C-termini, respectively. As a first step, we tested whether this construct (YNβ1a-YC) was functional after expression in β1KO myotubes, which are null for endogenous β1. In particular, we compared it to YFP-β1a because previous work has shown that attachment of intact fluorescent proteins to the N- and/or C-termini has no obvious effect on function of β1. Both YFP-β1a and YNβ1a-YC constructs produced robust Ca2+ currents, which were not present in non-transfected β1KO myotubes (Fig. 1A). Furthermore, the currents resulting from expression of the two constructs were similar in both magnitude and voltage-dependence as reflected in the peak current-voltage (I-V) relationships (Fig. 1B).

Because both channel function and membrane trafficking are affected by β subunits, we assessed membrane expression by measuring intramembrane charge movements after block of L-type ionic current by addition of 0.5 mM CdCl2 and 0.1 mM LaCl3 to the external solution. Representative charge movements for a depolarization to +30 mV are shown in Figure 1C. The currents resulting from expression of the two constructs were similar in both magnitude and voltage-dependence as reflected in the peak current-voltage (I-V) relationships (Fig. 1B). To test for EC coupling, myotubes were depolarized by a 5 sec application of 80 mM KC1. As shown in Figure 2, left, this depolarization did not elicit a visible response from a β1KO myotube, but caused pronounced, qualitatively similar contractions of β1KO myotubes expressing either YFP-β1a or YNβ1a-YC. Moreover, the charge movements for YFP-β1a and YNβ1a-VC had similar voltage dependence (Fig. 1D).

To test for EC coupling, myotubes were depolarized by a 5 sec application of 80 mM KC1. As shown in Figure 2, left, this depolarization did not elicit a visible response from a β1KO myotube, but caused pronounced, qualitatively similar contractions of β1KO myotubes expressing either YFP-β1a or YNβ1a-VC. Moreover, the charge movements for YFP-β1a and YNβ1a-VC had similar voltage dependence (Fig. 1D).

To further probe the positional restraints on the β1a N- and C-termini, we tested for the binding of gold-streptavidin conjugates applied to myotubes expressing β1a constructs with a biotin acceptor domain (BAD) fused to either the N- or C-terminus. Large (>5 nm) gold-streptavidin conjugates could bind to either terminus, suggesting that the N- and C-termini are not constrained to be in tight apposition to one another. The results with BiFC and gold-streptavidin bindings provide a proposed model of the arrangement of β1a subunits within DHPR tetrad.

Results

Functional equivalence of YNβ1a-VC and YFP-β1a. As one approach for probing the spatial relationships between the N- and C-termini of the β1a subunit of the skeletal muscle L-type CaV channel (DHPR), we tested whether BiFC would occur for YFP amino acids 1–158 ("YN") and 159–238 ("YC") fused to the β1a N- and C-termini, respectively. As a first step, we tested whether this construct (YNβ1a-VC) was functional after expression in β1KO myotubes, which are null for endogenous β1. In particular, we compared it to YFP-β1a because previous work has shown that attachment of intact fluorescent proteins to the N- and/or C-termini has no obvious effect on function of β1. Both YFP-β1a and YNβ1a-VC constructs produced robust Ca2+ currents, which were not present in non-transfected β1KO myotubes (Fig. 1A).
BiFC occurs for YN-β1a-YC. Having established the functional equivalency of YFP-β1a and YN-β1a-YC, we next compared the two constructs in terms of fluorescence intensity and subcellular distribution after expression in β1KO myotubes. A comparison of low-magnification (10X) images, which were obtained with identical confocal settings from fields having comparable coverage by myotubes, revealed that the fraction of detectably yellow cells was similar in four dishes of β1KO myotubes transfected with YFP-β1a (38/310 cells) and four dishes transfected with YN-β1a-YC (33/272 cells). Examined at higher power (63X), myotubes transfected with either construct displayed large numbers of yellow fluorescent puncta superimposed on a diffuse, yellow background (Fig. 3A). These puncta represent presumptive sites of plasma membrane junctions with...
the sarcoplasmic reticulum at which DHPRs containing CaV1.1 and β1a interact with RyR1, whereas the diffuse background likely represents cytoplasmic β1a not associated with CaV1.1.27,28 Thus, it appears that BiFC occurred for YN-β1a-YC located either cytoplasmically or incorporated into juncionally inserted DHPRs. This result is consistent with earlier work showing that FRET occurred between CFP and YFP attached to the N- and C-termini of β1a both in the cytoplasm and in junctional DHPRs.27 To compare the intensity resulting from fluorescence complementation with that resulting from intact YFP, four 512 × 512 pixel images were obtained at 63X of non-transfected β1KO myotubes transfected with YFP-β1a or YN-β1a-YC. In similar images of non-transfected β1KO myotubes, we observed that 99.6% of all pixels had intensities < 20, which was thus used as a lower threshold for the analysis of the transfected myotubes. After exclusion of pixel intensities < 20, the average fluorescence intensity for YN-β1a-YC was 52 ± 35 (mean ± S.D.; n = 18,503) compared with 64 ± 50 (n = 19,518) for YFP-β1a (different at p < 0.0001, unpaired Student’s t-test). A comparison of intensity histograms (Fig. 3B) revealed that this difference in average intensity was a consequence of the fact that there were more “dim” pixels and fewer bright pixels for YN-β1a-YC (red line) than for YFP-β1a (black line). In particular, intensities of 20–99 accounted for 16,781 and 15,918 pixels, and intensities of 100–255 for 1,722 and 3,600 pixels in the images obtained from YN-β1a-YC and YFP-β1a, respectively. The lower fluorescence intensity for YN-β1a-YC is typical of the BiFC assay and is likely because complementation is incomplete even when the YN moiety is functional for EC coupling.26

The L134P mutation eliminates BiFC between the N- and C- termini of β1a. To test whether the fluorescence complementation observed for YN-β1a-YC would be disrupted by alteration of the "MAGUK" core structure, we introduced the L134P mutation into the SH3 domain, which is structurally conserved between CaMKⅢβ subunits.26 Previous work had shown that the L134P mutation within β1a, and the corresponding mutation (L93P) within β2a, altered inactivation of co-expressed CaV2.168 and that the L93P mutation greatly reduced (although did not eliminate) the ability of β2a to produce membrane trafficking of CaV1.2.27 Furthermore, the homologous mutation (L460P) interferes with the interaction of the SH3 and GK domains of the MAGUK protein PSD-95.30 Thus, we constructed YN-β1aL134P-YC, as well as YFP-β1aL134P to serve as a control. Figure 4A demonstrates that the subcellular distribution of YFP-β1aL134P expressed in β1KO myotubes was much different than the dispersed, small puncta characteristic of YFP-β1a (Fig. 3A, top panel). In particular, 2–3 d post-transfection, YFP-β1aL134P was present in some cells as large juxta-nuclear clusters (Fig. 4A, top panel), which may represent an accumulation of misfolded protein in aggresomes,26 whereas in other cells it was more uniformly distributed and produced a faint, diffuse yellow fluorescence; this diffuse yellow fluorescence was sometimes also present in cells with aggregates but is not visible in the top panel of Figure 4A to avoid extreme over-saturation of the aggregates. By 4–5 d post-transfection, however, the aggregates had largely disappeared and YFP-β1aL134P was diffusely distributed in most cells at a level that was easily distinguishable from background (Fig. 4A, bottom panel).

Although the L134P mutation caused a significant alteration in the subcellular distribution of β1a, it appeared not to entirely eliminate its ability to direct membrane expression of DHPRs. Thus, measureable Ca2+ current was present in one cell examined 3 d post-transfection with YFP-β1aL134P, and in half of all cells examined 4–5 d post-transfection (Fig. 4B), whereas no Ca2+ current
an experiment in which we co-transfected β with YFP–β had been inserted between residues 726 and 727 of the II-III β–not contract when depolarized with 80 mM KCl (day 3, n = 4; Ca2+ currents were detected in non-transfected β). Table 1 shows that the presence of L-type Ca2+ current in myotubes expressing YFP–β–not bind strongly to the aggregated β1aL134P mutant. Another possibility is that the expression levels were sufficiently high in the tsA201 cells to allow non-specific YN–YC complementation. Indeed, complementation also occurred in tsA201 cells after expression of YN and YC fragments not attached to β1a or YN–YC which after co-expression with YN–β1aL134P and CaV1.1 (726-CFP-727), in which CFP had been inserted between residues 726 and 727 of the II-III loop. As shown in Figure 4D at 2 d post-transfection, the YFP–β1aL134P was aggregated around nuclei. This pattern was not present for CaV1.1(726-CFP-727), which indicates that it does not bind strongly to the aggregated β1aL134P but also does not exclude the possibility that it binds, perhaps weakly, to β1aL134P that is more difficuly-distributed in the cytoplasm.

Taken together, the fluorescence and electrophysiological data indicate that the L134P mutation altered the conformation of β1a such that its trafficking and function were affected. Importantly, this altered conformation could be directly detected by the absence of fluorescence complementation for the construct YN–β1aL134P–YC. In particular, we failed to detect yellow fluorescence above background in a total of eight dishes of β1KO myotubes from two separate primary cell cultures 3–5 d after transfection with YN–β1aL134P–YC (YPβ1a and YFP–β1aL134P were transfected in parallel experiments as qualitative positive controls). A representative example of a myotube from a β1KO culture 5 d after transfection with YN–β1aL134P–YC is shown in Figure 4E. It is assumed that subcellular trafficking of YN–β1aL134P–YC is similar to that of YFP–β1aL134P–YC, these data support the idea that YN–β1aL134P–YC is present at both 3 and 5 d post-transfection, but that BiFC does not occur for the misfolded β1aL134P mutant.

Absence of BiFC in myotubes after co-expression of YN–β1aL134P–YC and YC–β1a-YC. Because DHPRs in junctions of the plasma membrane with the sarcoplasmic reticulum are closely packed in arrays of tetrads, the punctate fluorescence observed in β1KO myotubes expressing YN–β1a–YC (Fig. 3A) could have arisen intramolecularly between N- and C-termini of individual β1a subunits and/or intermolecularly between N- and C-termini of subunits adjacent to one another in tetrads. Thus, we constructed YN–β1a–YN and YC–β1a–YC, which after co-expression could only produce intermolecular fluorescence complementation. Specificity, if YN–β1a–YN and YC–β1a–YC assembled randomly into tetrads and produced intermolecular BiFC with the same efficiency as occurs for YN–β1a–YC in tetrads, then the total number of fluorescence complementation events per tetrad would be 50% of those occurring for YN–β1a–YC. Before testing this prediction, we performed control experiments in tsA201 cells that lack Ca2+ channel CaV1.1 and CaV2 subunits and thus would yield cytoplasmic localization of expressed β1a constructs. After transfection of tsA201 cells with YN–β1a–YC, yellow fluorescent cells were present, consistent with the notion that N- and C-termini of cytoplasmic β1a are closely apposed to one another, as well as with previous FRET measurements on β1a subunits in the cytosol of myotubes lacking CaV1.1. Surprisingly, however, we also observed fluorescent tsA201 cells after co-transfection with YN–β1a–YN plus YC–β1a–YC. Thus, intermolecular BiFC appeared to have occurred for YN–β1a–YN plus YC–β1a–YC perhaps due to the oligomerization of the CaVβ subunits that has been recently reported for heterologous expression systems that lack the CaVβ subunit. Another possibility is that the expression levels were sufficiently high in the tsA201 cells to allow non-specific YN–YC complementation. Indeed, complementation also occurred in tsA201 cells after expression of YN and YC fragments not attached to β1a, with the fraction of yellow cells (6/266) being about 14% of that observed (41/262) after transfection with intact YFP (data not
Figure 4. The point mutation L134P in β1a impaired trafficking and L-type channel function, and altered β1a folding as indicated by loss of BiFC. (A) Mid-level confocal sections of β1KO myotubes expressing YFP-β1aL134P at days 3 (top) and 5 (bottom) post-transfection. (B) Distribution of peak Ca\(^{2+}\) current densities at +30 mV of β1KO myotubes expressing YFP-β1aL134P at day 3 (black bars, n = 9) and days 4–5 (gray bars, n = 9); cells with either small outward currents or the smallest inward currents were grouped together. Mean peak current densities were 0.41 ± 0.43 and -0.14 ± 0.89 pA/pF at 3 and 4–5 d post-transfection, respectively. (C) Average integral of the Ohm component of the charge movement vs. voltage relationships in β1KO myotubes expressing YFP-β1aL134P 3 d (black circles, n = 3) and 4–5 d (gray circles, n = 5) post-transfection. Error bars represent ± SEM. Averaged data points were fit with Equation 1, with values of Q_{max} (2.7, 3.4) V^{1/2} (-1.4, -1.4 mV) and k (10.1, 16.9 mV) for YFP-β1aL134P day 3 and day 4–5, respectively. The fit of the averaged β1KO data from Figure 2E is shown as a reference (dashed line). (E) Ca\(_{v}\) 1.1 did not co-localize with the juxtanuclear aggregates of β1aL134P. Two to three days after co-expression in β1KO myotubes, YFP-β1aL134P was typically present in presumed aggresomes whereas Ca\(_{v}\) 1.1(726-CFP-727) was present in a reticular pattern. (F) Representative cell 5 d after transfection of β1KO myotubes with YN-β1aL134P-YC. No significant yellow fluorescence was seen with the same confocal settings used to acquire the image shown in A for YFP-β1aL134P at day 5 post-transfection. Similarly, no significant yellow fluorescence was seen for YN-β1aL134P-YC at day 3 post-transfection (not shown). In (A), (D) and (E), the red ellipses indicate approximate outlines of nuclei. Red scale bars represent 5 μm.
shown). Such non-specific complementation appeared to occur with a lower incidence in β1KO myotubes, where co-transfection of YN and YC fragments yielded yellow fluorescence in 40 cells in five dishes that each contained hundreds of myotubes (two separate cultures) which was only about 4% of that observed after expression of YFP (338 cells in two dishes from two separate cultures).

Because the control experiments in tsA201 cells indicated that overexpression might lead to intermolecular BiFC between non-interacting proteins, we compared β1KO myotubes after transfection either with YN-β1a-YC (2 μL LT-1 and 1.5 μg cDNA per 35 mm dish) or with YN-β1a-YN plus YC-β1a-YC (2 μL LT-1 and 1.5 μg of each cDNA per 35 mm dish). In the myotubes transfected with YN-β1a-YC, yellow fluorescence was observed (Fig. 5, bottom left panel) in 12% of cells, whereas detectable yellow fluorescence was not observed (Fig. 5, bottom right panel) with the same confocal settings in eight dishes co-transfected with YN-β1a-YN plus YC-β1a-YC.

The results above are consistent with the hypothesis that BiFC does not occur in myotubes co-transfected with YN-β1a-YN plus YC-β1a-YC because the organization of DHPRs in tetradic positions the N- and C-termini of adjacent β1a subunits too far apart for intermolecular fluorescence complementation to occur.

If this is correct, then the yellow fluorescent puncta observed in β1KO myotubes transfected with YN-β1a-YC (Fig. 3A) must have arisen intramolecularly between N- and C-termini of individual β1a subunits. We thus tested whether intramolecular BiFC occurred for YN-β1a-YC co-expressed with CaV1.2 in dysgenic (CaV1.1-null) myotubes. Such co-expression resulted in yellow puncta preferentially localized near the surface (Fig. 6), as expected for CaV1.2-containing channels, which target to plasma membrane junctions with the SR. Importantly, CaV1.2 has substantial homology to CaV1.1, but does not assemble into tetradic arrays. Thus, the yellow puncta illustrated in Figure 6 must have arisen from intramolecular BiFC and this is likely also to be the case for the yellow puncta observed when YN-β1a-YC is associated with endogenous CaV1.1 after transfection of β1KO myotubes (Fig. 3). Accordingly, β1a subunits appear to be fully functional when the N- and C-termini are positioned close enough together to permit fluorescence complementation of attached YFP fragments.

Association of β1a with CaV1.1 in junctional DHPRs does not strongly constrain the position of the N- and C-termini. Although the present work indicates that the ability of β1a to function is compatible with its N- and C-termini being in close

### Figures

**Figure 5.** Lack of intermolecular BiFC between β1a subunits associated with CaV1.1 in junctional DHPRs. Top row: tsA201 cells were transfected either with YN-β1a-YC (left) or with YN-β1a-YN plus YC-β1a-YC (right). Yellow fluorescence indicated intramolecular (YN-β1a-YC) or intermolecular (YN-β1a-YN plus YC-β1a-YC) BiFC. Bottom row: after expression in β1KO myotubes, intermolecular BiFC occurred for YN-β1a-YC, but intermolecular BiFC did not occur for YN-β1a-YN plus YC-β1a-YC. All images were obtained at 10X (red scale bar indicates 20 μm) and were typical of the entire dish. The images in horizontal rows were captured with the same confocal settings. Note that at 10X, fluorescent puncta are not resolvable for YN-β1a-YC (compare the 63X image in Figure 3A, top panel).

**Figure 6.** BiFC of YN-β1a-YC co-expressed with CaV1.2 in a dysgenic myotube, as indicated by the presence of yellow fluorescent puncta near the surface. Confocal sections near the middle (left) and surface (right) of the myotube are shown. Since CaV1.2 does not assemble into tetradic arrays, the presence of yellow puncta indicates that BiFC arose as a consequence of the close apposition of the N- and C-termini of individual β1a subunits. Scale bar = 10 μm.
aposition, previous results indicate that such close apposition is not a requirement for function. In particular, L-type current and EC coupling are supported by β1a subunits with a CFP-YFP tandem attached to either the N- or C-terminus,13,28 or with CFP attached to one terminus and YFP to the other.27 Additionally, EC coupling appears not be affected by the binding of streptavidin to either the N- or C-termini, respectively, of the constructs YFP–β1a–BAD or BAD–β1a–YFP.25 To obtain additional information about the positional restraints on the N- and C-termini of β1a, we tested whether gold-streptavidin conjugates could bind to N- or C-terminal biotin, using YFP fluorescence to establish the localization of the β1a subunits and Alexa647 or Alexa594 to determine sites at which the conjugates bound. Because of their large size, the conjugates had to be applied to cells that had either been permeabilized with saponin (Fig. 7A) or to cells that had been briefly fixed with paraformaldehyde and then permeabilized with Triton X-100 (Fig. 7B–D). Streptavidin conjugated to 1 nm gold appeared to have good access to the C-terminus (Fig. 7A) and N-terminus (not shown) of β1a in junctional DHPRs. Similarly, 5 nm gold-streptavidin was able to bind to both the N-terminus (Fig. 7B) and C-terminus (Fig. 7C) of β1a in junctional DHPRs. Testing the ability of the 10 nm gold conjugate to bind was problematic because in most instances there was poor penetration and/or diffusion. However, in a single cell (out of seven examined) there appeared to be clear binding to the β1a N-terminus (Fig. 7D). The ability of gold-streptavidin conjugates to bind provides evidence that neither the N-terminus nor C-terminus of β1a is constrained such that it is closely opposed by other structures associated with junctional DHPRs.

Discussion

In the current study, we fused non-fluorescent N- and C-terminal fragments of YFP (“YN” and “YC”), or the biotin acceptor domain (“BAD”), to the N- and/or C-termini of the calcium channel β1a subunit to gain insight into its structure and spatial organization within tetrad arrays (1) of Cav1.1-containing calcium channels (DHPRs) in skeletal muscle cells. Addition of the YFP or BAD fragments to β1a did not appear to interfere with β1a function (Figs. 1 and 2; refs. 26 and 27). We found (Fig. 3A) that expression of the construct YN–β1a–YC in β1KO myotubes resulted in the presence of numerous yellow fluorescent puncta, which are presumptive clusters in the plasma membrane of calcium channels that contain β1a and Cav1.1 and which are arranged as tetrads;15 these puncta were superposed on a background of diffuse yellow fluorescence, which likely represents β1a subunits not associated with Cav1.1.15,25 The fluorescence complementation was efficient since the fluorescence intensity of myotubes transfected with YN–β1a–YC was only slightly lower than that of myotubes transfected with YFP–β1a (Fig. 3B). To test whether the BiFC observed for YN–β1a–YC depended on the correct folding of β1a, we used the point mutation L134P which lies within the SH3 domain that is highly conserved between Cavβ isoforms.25,26 The L134P mutation strongly impaired the ability of β1a to direct the targeting and function of Cav1.1 (Fig. 4A–D), and abolished BiFC between the N- and C-termini of β1a (Fig. 4E), presumably due to a structural alteration of the β1a subunit. BiFC was not observed in β1KO myotubes co-transfected with YN–β1a–YN plus VC–β1a–YC (Fig. 5), which is consistent with the hypothesis that the arrangement of β1a subunits in DHPR tetrads positions the N- and C-termini too far apart to support inter-molecular complementation, and that the punctate fluorescence observed in myotubes transfected with YN–β1a–YC arose intra-molecularly within single β1a subunits. Furthermore, expression in dyogenic myotubes (null for Cav1.1) of YN–β1a–YC plus Cav1.2 resulted in fluorescent puncta (Fig. 6), which presumably were a consequence of intra-molecular BiFC since Cav1.2 produces clusters of channels that are not arranged as tetrads.26 Thus, when β1a is complexed with Cav1.2, and most likely with Cav1.1 as well, the N- and C-termini can closely appose one another. However, such close apposition does not appear to be obligatory because gold-streptavidin probes had access to the N- and C-termini of β1a co-assembled with Cav1.1 into DHPR clusters in myotubes (Fig. 7).

Although the presence of BiFC is consistent with there being a naturally occurring association between the sites to which the YFP

![Figure 7](https://example.com/image7.png)

Figure 7. Large probes have access to the N- and C-termini of β1a in junctional DHPRs. β1KO myotubes were transfected with YFP–β1a–BAD (A) and (C) or with BAD–β1a–YFP (B) and (D). The cells were then either permeabilized by a 30 sec exposure to saponin (A) or fixed for 10 min with paraformaldehyde followed by permeabilization with Triton X-100 (C) and then exposed to 1 nm fluoro-nanogold streptavidin (A), 5 nm gold-streptavidin (B) and (C) or 10 nm gold-streptavidin (D). Except for the 1 nm gold-conjugate which had been pre-labeled with Alexa647, the position of the gold-streptavidin complexes (shown in red, with YFP fluorescence in green) was determined by subsequent labeling with biocytin-Alexa594. The YFP and streptavidin fluorescence images are shown superimposed in the rightmost panels of (A–D). Scale bar = 10 μm.

www.landesbioscience.com Channels 33
fragments are attached, it was evident that BiFC could occur even when such an association did not seem likely. In particular, we found that yellow fluorescence was present in ta201 cells co-transfected with YN-β1a-YN plus YC-β1a-YC (Fig. 5, top right). It is possible that this represented intermolecular BiFC dependent on oligomerization of the β1a subunits.52,53 but we also found that yellow fluorescence was present in ~2% of ta201 cells co-transfected with YN plus YC (not shown). However, even though non-specific fluorescence complementation was an issue, it was nonetheless observed in ~1% of ta201 cells co-transfected with YN-β1a-YN plus YC-β1a-YC (Fig. 5, top right), the yellow fluorescence in cells transfected with YN-β1a-YC (Fig. 5, top left panel) was more frequent and brighter, as would be expected if close apposition can occur between the N- and C-termini of individual β1a subunits which are free in the cytoplasm and not complexed with a Ca V subunit. Additionally, the existence of FRET between fluorescent proteins attached to the N- and C-termini of β1a constructs expressed in dysgenic myotubes54 provides further support that the N- and C-Termini of non-complexed β1a subunits can be closely apposed.

A variety of evidence suggests that for β1a bound to CaV1.1, just as for free β1a, the N- and C-termini are able to approach one another closely, and that this accounts for the punctate fluorescence observed in j1KO myotubes transfected with YN-β1a-YC. Certainly, the hypothesis that there are no large disparities in the disposition of the N- and C-termini is consistent with the crystallographic data showing that the conserved core structure of β1a is very similar whether or not it is bound to the interacting domain of the CaV1.2 L1-loop.55 Indeed, we observed punctate fluorescence in dysgenic myotubes transfected with YN-β1a-YC plus CaV1.2. This punctate fluorescence strongly implies the occurrence of BiFC between N- and C-termini of individual β1a subunits bound to CaV1.2 because the alternative, BiFC between β1a subunits adjacent to one another, seems unlikely given the irregular disposition in the plasma membrane of CaV1.2 expressed in dysgenic myotubes.54 In addition to the "positive" evidence that close apposition can exist between the N- and C-termini of individual β1a subunits complexed with CaV subunits, both our current experiments, and previous work, provide "negative" evidence that close apposition does not occur between the termini of adjacent β1a subunits that are complexed with CaV1.1 in arrays of DHPR tetramers.56 In particular, the earlier work found that measurable FRET was present after expression in j1KO myotubes of YFP-β1a-CFP but not after expression of equimolar mixes of β1a subunits tagged on one terminus with YFP and on the other with CFP.57 Since the presence of FRET indicates that the fluorophores are separated by <10 nm, the absence of FRET suggests that β1a subunits expressed in CaV1.1 subunits in DHPR tetramer. However, because this earlier study relied on modest changes in the intensity of cyan fluorescence after photo-bleaching of YFP, it could have failed to detect weak FRET interactions. Thus, further probing the spatial separation between the termini of adjacent β1a subunits was an important part of our current studies. For this, we co-transfected j1KO myotubes with YN-β1a-YN plus YC-β1a-YC because the use of double tagging, as opposed to single tagging, doubled the number of possible intermolecular complementation events, although the average number of possible complementation events for YN-β1a-YN plus YC-β1a-YC randomly assembled into DHPR tetramers would still be only half that of YN-β1a-YC. Nonetheless, if intermolecular BiFC had occurred, it should have been easily detectable given the bright, yellow fluorescent puncta present in j1KO myotubes after transfection with YN-β1a-YC. However, no fluorescence was detected in a total of eight single experiments, even in dysgenic myotubes, after transfection with YN-β1a-YN plus YC-β1a-YC. Of course, this test for intermolecular BiFC depended on the successful co-transfection of myotubes with both cDNA constructs. One argument that such co-transfection is likely to have occurred is that yellow fluorescence was present in ~12% of myotubes transfected with YN-β1a-YC (1.5 μg of cDNA per dish). Thus, ~1.5% of the j1KO myotubes co-transfected with YN-β1a-YN and YC-β1a-YC should have expressed both constructs even if the probability of successful transfecion of a cell with one of the constructs was independent of transfecion with the other construct; such independence seems unlikely given that the two cDNAs were pre-mixed (1.5 μg of each cDNA) prior to addition to the dishes. Additionally, we also examined myotubes that had been co-transfected with free YN plus β1a- YC (1.5 μg of each cDNA per dish). In eight dishes co-transfected with YN plus β1a-YC, yellow fluorescence was detectable in four cells (data not shown), which likely represents a minimal estimate for co-transfection efficiency since the production of yellow fluorescence depended upon both co-transfection of the two constructs and sufficient expression of free YN to produce FRET fluorescence. As expected, yellow fluorescence was dependent on both co-transfection of the two constructs and sufficient expression of free YN to produce FRET.
domains are highly conserved among all CaV
its arrangement in DHPR tetrads. Because the SH3 and GK
exceeded the capacity of the proteasomal pathway.31 Presumably
sented its accumulation into aggresomes, which are cytoplasmic
s been slightly larger at both ~3 and 4
comparison of the magnitude of the charge restored by
control
and another in tetrads. Figure 8C illustrates additional constraints: that BiFC not occur between the termini of β1a subunits in neighboring tetrads and that DHPRs in neighboring tetrads not occlude the binding of gold-streptavidin conjugates; these conditions would be violated if the β1a N- and C-termini were shifted ~30° counter-clockwise.
In conclusion, our current results provide constraints that can be used to test models for the positioning of β1a in DHPR tetrads. More generally, the use of BiFC appears to be a useful tool for analyzing the positioning of domains that are sufficiently disordered that they do not produce crystal structures. In the case of Cavβ subunits, the sequence differences in D1, D3 and D5 are likely not only to result in different structures but also to result in the functional differences that have been described for the different β-subunits. In future experiments, it will be of interest to determine whether YFP fragments attached to divergent domains of different β-subunits result in BiFC like that we have found for these fragments attached to the N- and C-termini of β1a.

Materials and Methods
cDNA constructs. cDNAs encoding β1a with enhanced yellow fluorescent protein (YFP) and a biotin acceptor domain (BAD) fused to the N- or C-termini (YFP-β1aBAD, BAD-β1a-YFP) were constructed as described previously.32,33 YN (YFP amino acids 1–158) and YC (YFP amino acids 159–238) cDNA constructs were originally created by the laboratory of Dr Catherine H. Berlot and described previously.33 Rabbit β1a (GenBank accession number M25514) was previously cloned into pEYFP-C1 (Clontech) and acted as our control.34 To create YN-β1a-YC, we first made YN fused to an N-terminal fragment of β1a (YN-β1aNC) and a C-terminal fragment of β1a fused to YC (β1aNC-YC) with a two-step PCR method. In the first step, a unique 3′XhoI site and double glycin linker were

post-transfection, YFP-β1aL134P was found in juxtanuclear aggregates (Fig 4A, upper panel), which were never observed after comparable transfection of either YFP-β1a or YN-β1a-YC (Fig 3A). This distribution of YFP-β1aL134P most likely repre-
sent its accumulation into aggresomes, which are cytoplasmic
deposits of misfolded and/or overexpressed proteins that have exceeded the capacity of the proteasomal pathway.35 Presumably
because the transient expression peaked and then declined, these
juxtanuclear aggregates disappeared and YFP-
 became punctate fluorescence like that resulting from expression of YFP-β1a or YN-
β1a-YC in β1KO myotubes. Despite greatly altering trafficking, the L134P mutation did not appear to eliminate membrane targeting entirely because expression of YFP-β1aL134P resulted in the presence of small inward calcium currents in half of all cells 4–5 d post-transfection (Fig 4B), and caused change movements to be slightly larger at both ~3 and 4–5 d after transfection than in control β1KO myotubes (Fig 4C). With β1KO as a reference, a comparison of the magnitude of the change restored by Y141A, with that restored by wild-type β1a, indicates that β1aL134P was about 25% as effective as wild-type β1a in supporting membrane trafficking of Cav1.3. This is similar to the ability of β2a bear-
ing the homologous mutation (L93P) to support expression of Cav1.2 in HEK293 cells.17 Interestingly, however, both β1aL134P and β2aL93P appeared to produce normal membrane expression of Cav1.2 in oocytes,36 although endogenously expressed β-subunits that have high sequence similarities to β1a, indicates that
β1a is like that determined crystallographically for β2a.23,35 This is indicated in Figure 8A by green β-helices and red β-strands for the SH3 domain, and by blue β-helices and orange β-strands for the GK domain. Because crystallographic information is not available for them, the divergent regions (D1, D3 and D5) are represented with black dots. Although the spatial dimensions and orientations of these divergent regions are presently unknown, we propose on the basis of our current study that the N- and C-termini of a β1a subunit can approach one another closely enough to allow complementation between YN and YC, resulting in the production of a fluorescent YFP molecule. Specifically, given that the fluorescent protein β-barrel is approximately 3 nm × 8 nm,26 and that the YN and YC fragments were each attached via a double glycine linker (~1 nm), it seems likely that the β1a N- and C-termini can be separated by as little as ~5 nm or less.

Electron microscopic analysis of freeze-fracture replicas and the DHPR structures revealed by single particle analysis remains elusive. In particular, the vast (~300 nm) subunit should be a major component of the DHPR analyzed by single particle analysis (constituting ~40% of the total mass), but the nearly complete ablation of β2-3a has no discernible effect on the size or distribution of tetradic particles.44 Thus, alternative models are possible for the arrangement of DHPRs in tetrads.45 None-theless, our current results provide a useful constraint for assigning the position of β1a in tetrads (Fig. 4B). This shows an arrangement of DHPRs (denoted by dark blue, oval outlines) relative to RyR1 (black square) similar to that proposed by Wolfs et al.35 Within the DHPR, β1a is indicated by the gray oval which has dimensions that would accommodate the Ca2+/β core structure. For three of the four tetradic DHPRs, β1a is shown in Figure 8B such that BiFC can occur between YN and YC in the construct YN-β1a-YC, but, as shown for the fourth tetradic DHPR, the β1a N- and C-termini have sufficient positional freedom to allow the binding of gold-streptavidin conjugates to BAD-β1a-YFP and to YFP-β1a-BAD so fused, permethylated myotubes (Fig 7). However, the positioning of the β1a subunit appears to be such that this positional freedom is not sufficient to allow BiFC to occur between β1a in DHPRs adjacent to one another in tetrads. Figure 8C illustrates additional constraints: that BiFC not occur between the termini of β1a subunits in neighboring tetrads and that DHPRs in neighboring tetrads not occlude the binding of gold-streptavidin conjugates; these conditions would be violated if the β1a N- and C-termini were shifted ~30° counter-clockwise.

In conclusion, our current results provide constraints that can be used to test models for the positioning of β1a in DHPR tetrads. More generally, the use of BiFC appears to be a useful tool for analyzing the positioning of domains that are sufficiently disordered that they do not produce crystal structures. In the case of Cavβ subunits, the sequence differences in D1, D3 and D5 are likely not only to result in different structures but also to result in the functional differences that have been described for the different β-subunits. In future experiments, it will be of interest to determine whether YFP fragments attached to divergent domains of different β-subunits result in BiFC like that we have found for these fragments attached to the N- and C-termini of β1a.
Figure 8. Models of β1a structure and arrangement in DHPR tetrads. (A) Ribbon structures of the conserved CaV β-sheet. Conserved regions are indicated by dotted black lines and the L134 mutation site is highlighted in cyan (see text). The results described in this paper indicate that the β1a N- and C-termini are able to allow YN and YC to complement one another and produce a yellow fluorescent protein (yellow ribbon structure). (B) Model for the arrangement of DHPRs within a tetrad (adapted from ref. 27) consistent with the present results on BiFC and gold-streptavidin binding. The RyR1 homotetramer is represented by the black square. Blue ovals represent the entire DHPR complex, including CaV1.1 and the auxiliary subunits β1a, α2-d, and γ1. β1a is represented as dark gray ovals with the N and C termini close enough for YN and YC to complement one another and produce a yellow fluorescent protein (YFP, in yellow; shown for three of the four DHPRs). For one DHPR in the tetrad, a position of the N- and C-termini consistent with the binding of gold-streptavidin (gold circle) to YFP-β1a-BAD or to BAD-β1a-YFP is shown. The dotted black circle in the center acts as a reference with a diameter of ~10 nm. (C) DHPR array in which tetrads are opposed to every other RyR1 (dark and light black squares). In myotubes, these arrays may comprise several rows of RyR1.36
introduced onto the N- and C-termini of YN, respectively, via PCR. The primers used were 1, 5'TCGCAAGATGTGAGGCA
AGGCG3' and 2, 5'GCCATTCTCCGCCTGCTGTGGGCC
ATGATAGAC3'. The N-terminal β1a fragment was created with the primers 3, 5'GCCATGGGGGGTATGGTGAGCAAGGGC
3' and 4, 5'TCGCAAGATGGGCGGAGGGCGGCTCGCC and ended at the unique PstI site at nucleotide position 516 of β1a. In the second step, the two fragments were fused together via multiple denaturing and annealing cycles and then amplified with the addition of primers 1 and 6. Likewise, we introduced a double glycin linker to the N-terminus and a stop codon and unique NotI site to the C-terminus of YC with the primers 5, 5'GCCATGGGGGGTATGGTGAGCAAGGGC3' and 6, 5'GCCGGGCTGCTAGTTAGCATGCTGATCATG3'. The primers used to create the C-terminal β1a fragment which began at the unique NotI site were 7, 5'TCGCAAGAAGCAGGATCGGCTGACAGG3' and 8, 5'TGCTTTACCCGCTATGGC
ATGTCCCTGCG3'. The two fragments were fused together via multiple denaturing and annealing cycles and then amplified with the addition of primers 6 and 7. Both YN-β1a-YC and β1a-YC fusion fragments were subcloned into the pCR2.1 vector (Invitrogen, Grand Island, NY) and sequenced. Correct fragments were excised with either XhoI and NotI and ligated into a similarly XhoI and NotI digested unlabeled β1a parent construct27 for the final YN-β1a-YC construct, or a NotI and NotI digested β1a parent construct for the final β1a-YC construct.

The same two-step PCR method was utilized to create both YN-β1a-YN and YC-β1a-YN. A β1a-YN fusion fragment was created with primers 7 (above) and 9 and digested with XhoI and NotI and ligated into a similarly XhoI and NotI digested YF-CaV1.1-YFP construct. Next, we created a YF-CaV1.1-YFP construct using a modified cEF-CFP (Cerulean) as a template and using the primers 5, 5'ACTAGTTGGTGAGGTGGGAGGTGTGA22
GTGACATCTGAGGCGGCGG3' and 6, 5'ACTAGTTGGTGAGGTGGGAGGTGTGA22
GTGACATCTGAGGCGGCGG3'. The primers used to create the C-terminal β1a fragment which began at the unique XhoI site were 10, 5'TCGCAAGAAGCAGGATCGGCTGACAGG3' and 11, 5'TGCTTTACCCGCTATGGC
ATGTCCCTGCG3'. These two PCR fragments were fused together via multiple denaturing and annealing cycles and then amplified with the addition of primers 13 and 14. The N-terminal PCR fragment was then excised with NotI and the enzyme cuts were allowed to self-ligate to produce the final YN-β1a-YN construct. A similar construct, CaV1.1β(YF-CaV1.1-YFP-727) was previously shown to be functional for both EC coupling and L-type Ca2+ current31. All subcloned fragments and final constructs were sequenced at the DNA Sequencing and Analysis Core of the CU Cancer Center at the University of Colorado Anschutz Medical Campus. All restriction enzymes were purchased from New England Biolabs.

Cell culture and cDNA transfection. Primary cultures of β1KO skeletal myotubes were prepared from limbs of E18
fetuses, as described previously32 in accordance with NIH guidelines of the Institutional Animal Care and Use Committee, University of Colorado Anschutz Medical Campus. Briefly, the dissected muscles were digested in 0.125% trypsin (w/v in rodents' Ringer's modified Eagle's medium with high glucose (Mediatech) 10% horse serum, and 10% fetal bovine serum, and plated on 35 mm BD Falcon plates. Primary 103 cells per dish. Cultures were grown in a humidified incubator at 37°C in 5% CO2. Both YN and YC constructs were transfected at 4-6 day, the plating medium was replaced with a differentiation medium (Dulbecco's modified Eagle's medium with high glucose (Mediatech) 10% horse serum, and 10% fetal bovine serum, and plated on 35 mm BD Falcon plates. Primary 103 cells per dish. Cultures were grown in a humidified incubator at 37°C in 5% CO2. After myoblast fusion had begun (4-6 day), the plating medium was replaced with a differentiation medium (Dulbecco's modified Eagle's medium with high glucose, supplemented with 2% horse serum). Except as noted below, cDNA transfection was performed during the myoblast fusion stage with the polyamine TransIT™-LT1 transfection reagent (Mirus Bio). Cells were exposed to a serum free, OptiMemI (Invitrogen) transfection solution for 2
6 h containing 1.5 l:1.5 μl cDNAs. 44 The cells were transfected with a mix containing 1.5 μg each of both constructs. All other transfections were performed -2 d after the change to differentiation medium. Nuclear injection was used for transfection with YN-β1a-YC (5 ng/μl) plus CaV1.2 (50 ng/μl). Transfection with YFP-β1a-BAD or BAD-β1a-YFP was performed either by nuclear injection (5-100 ng/μl) (26) of the cDNAs or by exposure for 2 h to HSV virions (2 × 105 particles/ml) kindly provided by Dr P.D. Allen) containing the cDNAs.26 The cells...
were then changed into a medium in which the biotin present in the 2% horse serum was supplemented with an additional 1 μM biotin.

tA201 cells (ECACC) were initially plated on 10 cm Petri dishes (Fisher Scientific) and passaged a minimum of three times prior to experiments. For experiments, the cells were then plated at a density of 3.0 × 10^4 on 35 mm BD Falcon plastic culture dishes (Becton Dickinson) in media comprised of Dulbecco’s modified Eagle’s medium with high glucose and 10% fetal bovine serum. On day 2, cells were transfected with 3 μl of the Lipofectamine 2000 reagent (Invitrogen) and 1 μg of the cDNA of interest per 35 mm dish. For co-transfections, each 35 mm dish was transfected with 1 μg each of both constructs. On day 3, each dish of transfected tA201 cells was split and plated on four separate 35 mm glass coverslip dishes (MatTek). On day 4, cells were fixed with 4% paraformaldehyde (in PBS). For the 5 or 10 nm gold-conjugated streptavidin, the excitation/emission parameters were: YFP, 488 nm excitation via a 488/543 nm dual dichroic, 560 nm long-pass emission filter; Alexa568 or Alexa594: 543 nm excitation via a 514 nm or 458 nm, respectively, line of an argon laser, and directed to the cell via a 458/514 nm dual dichroic mirror.

Measurement of ionic currents and intramembrane charge movement. Whole cell voltage clamp analysis of Ca^2+ currents and intramembrane charge movements was performed 5–6 d after transfection as described previously. The “external solution” was comprised of sterile filtered (in millimolars): 145 TEA-Cl, 10 CaCl_2, 0.003 tetrodotoxin, and 10 HEPES, pH 7.4 with TEA-OH. The “internal solution” consisted of sterile filtered (in millimolars): 140 CsAsp, 10 Cs_2EGTA, 5 MgCl_2, and 10 HEPES, pH 7.3 with CsOH. Ionic currents were blocked for intramembrane charge movement studies with addition of 0.5 mM CdCl_2 and 0.1 mM LaCl_3 (final concentrations) to the external solution. All millimolar charge movements were corrected for linear capacitance and leak current using a −P/8 prepulse subtraction protocol (V_{prep} = −80 mV). Plots of peak calcium current (I) vs. test potential (V) were converted to conductance vs. potential according to

\[
G(V) = I/(V−V_{rev})
\]  
(Eqn. 1)

where the reversal potential (V_{rev}) was determined visually from the peak I-V plot. The voltage dependence of G and the integral of the ON transient (Q_{on}) for each test potential (V) were fit according to Equation 2:

\[
A = A_{max} / [1 + \exp (-|V_{1/2}−V|/k)]
\]  
(Eqn. 2)

where A_{max} is the maximal G_{max} or Q_{max}. V_{1/2} is the potential causing activation of half-maximal conductance or movement of half-maximal charge, and k is a slope parameter. Data analysis and traces for presentation was performed with SigmaPlot 10.0 software (Systat). Figures were arranged for final presentation with Adobe Illustrator CS4.

Application of gold-streptavidin. Gold-conjugated streptavidin was introduced into cells two days after transfection with cDNA for YFP, β_1a-YFP, or BAD–β_1a-YFP. For experiments with 1 nm gold, the cells were permeabilized for 30 sec with saponin (Sigma; 12 μg/ml) in internal solution (composition given above). Following wash in internal solution, cells were incubated in Alexa594-nanogold streptavidin (Invitrogen, 1:500 in internal solution) for 30 min. Excess gold-streptavidin was removed by washing cells with internal solution for 30 min, followed by post-fixation with 4% paraformaldehyde (in PBS). For the 5 or 10 nm gold-streptavidin conjugates (British BioCell Int.), which likely exceed the size of the pores made by saponin, mystocytes were first fixed with 4% paraformaldehyde for 10 min, and then permeabilized with Triton X-100 (Sigma; 0.1% in PBS) for 30 min. The cells were then incubated with 5 or 10 nm gold-streptavidin (1:100 in PBS) for 2–12 h followed by incubation with biocytin-Alexa568 (Invitrogen; 1:20,000) for 30 min to fluorescently label the streptavidin–gold conjugate.

Confocal fluorescence microscopy. Cells were imaged with a LSM 510 META laser scanning inverted confocal microscope (Zeiss) in rodents’ Ringers comprised of (in mM): 146 NaCl, 5 KCl, 2 CaCl_2, 1 MgCl_2, 11 glucose, and 10 HEPES, pH 7.4 with NaOH. For analysis of yellow or cyan fluorescence, excitation was via a 514 or 458 nm, respectively, line of an argon laser, and directed to the cell via a 458/514 nm dual dichroic mirror. The emitted fluorescence was directed to a photomultiplier equipped with a 530 nm long-pass filter for YFP or a 465–495 band-pass filter for CEP. For analysis of both YFP and Alexa568 or Alexa594, the excitation/emission parameters were: YFP, 488 nm excitation via a 488/543 nm dual dichroic, 505–530 nm band-pass emission filter; Alexa568 or Alexa594: 543 nm excitation via a 488/543 nm dual dichroic, 560 nm long-pass emission filter. Images were acquired as the average of four to eight line scans per pixel and digitized at 8 bits.

All data are reported in the mean ± SEM, unless otherwise noted. Statistical significance was tested with an unpaired Student’s t-test.

RCl membrane depolarization and myotube contractions. The ability of the β1a construct to support EC coupling after expression in β1KO mystocytes was assessed by the presence of evoked contractions in response to microperfusion with rodents’ Ringers in which K+ was increased to 80 mM by equimolar replacement of Na+. The solution was applied via a glass micropipette placed near the cell and controlled by a Picospritzer II (General Valve Co.) set at 5 sec and -3 psi. Images of the myotubes were acquired at a rate of -11 Hz and digitized at 8 bits. The contractions were recorded as the movement of a small region of interest on the edge of the myotube.

Protein modeling. Sequences for rabbit β1a and YFP were submitted to the Swiss-Model website at http://swissmodel.expasy.org/workspace. Results were manipulated with the DeepView (Swiss-Pdb-View) program. Final models were arranged in Adobe Photoshop 7.0 and Adobe Illustrator CS4 for figure presentation. The domains of the β1a subunit were oriented to correspond to the published crystal structure of the CaV2.2a subunit.13

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors of the study wish to thank Catherine H. Berlot, MD, PhD (Wein Center for Research at the Geisinger Clinic) for
permission to use the YFP-N (YN) and YFP-C (YC) cDNA constructs, Alchevsky and coworkers (University of Rochester Medical Center) for the initial idea to employ the BiFC technique and John Lucchese (University of Iowa) for information pertaining to the YN and YC constructs. This study was supported by grants from the Muscular Dystrophy Association (Development Grant MD44334 to D.C.S. and Research Grant MDA 761448 to K.G.), the National Institutes of Health (AR054750 and AR055104 to K.G.B.). A preliminary version of this work was published as an abstract and presented at a platform session: D.C. Sheridan and K.G. Beam, Abstract 27-Plat, 52nd Annual Meeting of the Biophysical Society, Long Beach, CA, February 2-6, 2008.

References
1. Black BA, Imagawa T, Campbell K, Franzini-Armstrong C. Structural evidence for direct interaction between the D-domain and the carboxy-terminal calmodulin-binding region of skeletal muscle Ca2+ release channels. J Biol Chem 2002; 277:10473-80; PMID:12000687; http://dx.doi.org/10.1074/jbc.M201520200
2. Obermair GJ, Tuluc P, Hacher RC, Assaytay CC. Calcium channel subunits from mouse brain. Proc Natl Acad Sci USA 2000; 97:3511-6; PMID:10766736; http://dx.doi.org/10.1073/pnas.97.07.3511
3. Okkotj J, Campbell KD. Auxiliary essential functional components of the volatile-gated calcium channel complex. Curr Opin Neurobiol 2003; 13:298-307; PMID:12850214; http://dx.doi.org/10.1016/S0959-4388(03)00044-4
4. Beam KG, Hennessy P. Excitation-contraction coupling in skeletal muscle. Mol Biology 2004; 41(11):1097-112; PMID:15418483
5. Chen WH, Li MH, Zhu Y, Hu Li, Yen YL, Romanovsky A, et al. Structural basis of the β3 subunit interaction of volatile-gated Ca2+ channels. Nature 2004; 429:267-91; PMID:15170217; http://dx.doi.org/10.1038/nature02441
6. Haslbeck MJ, Benovic JL, Dolphin AC, Wallace LA. Modelling of a volatile-gated Ca2+ channel β3 subunit as a basis for understanding its functional properties. P Natl Acad Sci USA 1999; 96:566-70; PMID:10484919; http://dx.doi.org/10.1073/pnas.993087596
7. McCoy AW, Nusbaum DA, Malvin JM, Fehokile KE, Nott GE, Bezu DS. Calcium channel function regulated by the SMG-Ⅲ module in β3 subunits. J Biol Chem 2004; 279:37641-6; PMID:15083620; http://dx.doi.org/10.1074/jbc.M404716200
8. Takahashi OE, Mirzaei J, Galaburda HM. Membrane-associated glycine-like linear properties of β3 subunits required for modulation of volatile-gated Ca2+ channels. Proc Natl Acad Sci USA 2004; 101:7193-8; PMID:15100405; http://dx.doi.org/10.1073/pnas.1007496101
9. Chen WH, Zhao XJ, Shuker RI, Patt TH, Chang CF, Sun K, et al. Role of a membrane-anchored β3 subunit in the formation and targeting of functional L-type Ca2+ channels. J Biol Chem 1995; 270:30656-64; PMID:959047; http://dx.doi.org/10.1074/jbc.270.40.30306
10. Nishimura R, Geiser U, Mitsumoto J, Giampietro HH, Palade GE. Differential effects of β3 and α1c subunits on complex formation with α1d subunits in α1d/β subunit coexpressing myotubes. J Biol Chem 1998; 273:10116-21; PMID:9595500; http://dx.doi.org/10.1074/jbc.273.15.1110
11. Beam KG, Abravaya KA, Volgin DP, Paladini MW, Bezu DS, Panigrahi AK, et al. Identification of a carboxy-terminal domain of neuronal Ca2+ release channel α1a and α1b subunits. J Biol Chem 2004; 279:35213-20; PMID:15267397; http://dx.doi.org/10.1074/jbc.M401432200
12. Johnston JA, Ward CL, Kippin TP, Aggounossi A, Zhang Y, Yamada Y, et al. Structural basis of the L-type Ca2+ channel β3 subunit functional core and its complex with α1d subunit domain. Nature 2004; 429:675-80; PMID:15170217; http://dx.doi.org/10.1038/nprot.2006.201
36. Tardif F, Roux M, Qiu N, Okose R, Zhou J, Scafati E, et al. A mouse oocyte β-subunit: Evidence for a role in the assembly/expression of voltage-gated calcium channels that is separate from its role in a regulatory subunit. Proc Natl Acad Sci USA 1997; 94:7573-8; PMID:9230842; http://dx.doi.org/10.1073/pnas.94.15.7573

37. Yang J, Moss LG, Phillips GN. The molecular structure of green fluorescent protein. Nat Biotechnol 1996; 14:1246-51; PMID:9051807; http://dx.doi.org/10.1038/nbt0996-1246

38. Wolf M, Heschel A, Glimmert H, Striessnig J, Geryzner V. Visualization of the domain structure of an L-type Ca²⁺ channel using electron cryo-microscopy. J Mol Biol 2003; 332:171-82; PMID:12848675; http://dx.doi.org/10.1016/S0022-2836(03)00899-4

39. Sayenov M, Lulko Y, Baker MI, Chris W, Hamilton M. Structures of the voltage-gated L-type Ca²⁺ channel by electron cryo-microscopy. Proc Natl Acad Sci USA 2002; 99:10537-42; PMID:12164678; http://dx.doi.org/10.1073/pnas.102636409

40. Gach MP, Chynchaqua C, Gasser C, Lopez JR, Beam KG, Fessenden JD, et al. Dihydropyridine receptor subunits is a critical domain for excitation-coupled calcium entry but not for formation of tetramers in skeletal myotubes. Biophys J 2008; 94:3023-34; PMID:18192372; http://dx.doi.org/10.1529/biophysj.107.118883

41. Buraei Z, Yang J. The β-subunit of voltage-gated Ca²⁺ channels. Physiol Rev 2010; 90:1461-506; PMID:20956231; http://dx.doi.org/10.1152/physrev.00057.2009

42. Banister RA, Papatopoulou S, Haarnam C, Beam KG. Effects of binding fluorescent proteins into the alpha1C/B-I-III loop into excitation-coupled coupling. J Gen Physiol 2009; 134:35-55; PMID:19344463; http://dx.doi.org/10.1085/jgp.200902401

43. Beam KG, Fessenden-Jamison C. Functional and structural approaches to the study of excitation-contraction coupling. Methods Mol Biol 1995; 52:285-306; PMID:7579955; http://dx.doi.org/10.1385/089947081800942

44. Wang Y, Fessenden JD, Pessah IN, et al. α2δ1 dihydropyridine receptor subunits is a critical domain for excitation-coupled calcium entry but not for formation of tetramers in skeletal myotubes. Biophys J 2008; 94:3023-34; PMID:18192372; http://dx.doi.org/10.1529/biophysj.107.118883

45. Bangham AD, Horne RW, Glauert AM, Dingle JT, Lucy JA. Action of saponin on biological cell mem- branes. Nature 1962; 196:952-5; PMID:13954375; http://dx.doi.org/10.1038/196952a0

46. Schönke T, Kopp J, Gans N, Pecht M. SWISS-MODEL: An automated protein homology-modelling server. Nucleic Acids Res 2003; 31:138-41; PMID:12683432; http://dx.doi.org/10.1093/nar/gkg150

47. Gans N, Pecht M. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997; 18:2744-51; PMID:9336803; http://dx.doi.org/10.1002/elps.1150181115

48. Kopp J, Schönke T. The SWISS-MODEL repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res 2004; 32:3634-6; PMID:15064801; http://dx.doi.org/10.1093/nar/gkh538

49. Arnold K, Besold U, Kopp J, Schönke T. The SWISS-MODEL workspace: A web-based environment for protein structure homology modeling. Bioinformatics 2006; 22:195-201; PMID:16311284; http://dx.doi.org/10.1093/bioinformatics/bti770